HealthDay reports from EASD that the oral GLP-1 showed cardiovascular safety comparable to daily insulin glargine shots in a trial presented Oct. 14, 2026.
Recap by typeshit. Full story at HealthDay.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Fast Company looks at GLP-1 drug users changing the hotel business and the new list of requests travelers are bringing with them.
Bloomberg reports people with schizophrenia taking GLP-1s for diabetes had fewer psychiatric hospital visits, hinting at another possible benefit.
Loading…